Trial site
Hopitaux Universitaires Pitie Salpetriere
Paris Cedex 13, 75651, FranceNot linked to an institution yet
- 21running trials
- 9closed trials
The trials here
What the 30 trials at this site are about, from their registry records.
- Phase
- Phase 315 trials
- Phase 28 trials
- Phase 12 trials
- Phase 1/22 trials
- Phase 42 trials
- Phase 2/31 trial
- Status
- Recruiting10 trials
- Completed9 trials
- Active, not recruiting7 trials
- Not yet recruiting4 trials
- Lead sponsor
- Centre Hospitalier Universitaire de Saint Etienne2 trials
- Federation Francophone de Cancerologie Digestive2 trials
- Kardigan Inc.2 trials
- UNICANCER2 trials
- University Hospital, Rouen2 trials
- and 20 more
Running trials
Not yet recruiting
A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma
NCT07612787· Phase 1/2· Centre Hospitalier Universitaire de Saint Etienne· Source
Recruiting
A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-OLE).
2026-526139-20-00· Phase 3· Kardigan Inc.· Source
Not yet recruiting
A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL
2024-516570-30-00· Phase 2· Centre Hospitalier De Versailles· Source
Recruiting
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
NCT07404865· Phase 3· Vor Biopharma· Source
Recruiting
A Study of the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy.
2025-522553-19-00· Phase 2/3· Kardigan Inc.· Source
Recruiting
Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma
NCT06254248· Phase 2· Assistance Publique - Hôpitaux de Paris· Source
Not yet recruiting
PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma
NCT07128290· Phase 2· Federation Francophone de Cancerologie Digestive· Source
Recruiting
MODULO
NCT06774872· Phase 3· Centre De Recherches Et D'Etudes Sur La Pathologie Tropicale Et Le Sida· Source
Recruiting
Design and Evaluation of an Individualized Biodrug Tapering Strategy Based on Biodrug Dosage: the MONITORA Study
NCT06528431· Phase 4· Centre Hospitalier Universitaire de Saint Etienne· Source
Recruiting
A study to assess the efficacy and safety of OATD-01 for the treatment of active pulmonary sarcoidosis.
2023-506642-23-01· Phase 2· Molecure S.A.· Source
Recruiting
Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy
NCT06107920· Phase 3· University Hospital, Rouen· Source
Active, not recruiting
A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus
NCT05835986· Phase 1· Hoffmann-La Roche· Source
Recruiting
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
NCT05503797· Phase 2· Fore Biotherapeutics· Source
Active, not recruiting
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
NCT05371093· Phase 3· Kite, A Gilead Company· Source
Active, not recruiting
Management of Anticoagulant Therapy Monitored by an Implantable Device With Telecardiology in Patients With Acute Coronary Syndrome Associated With de Novo Atrial Fibrillation Arrhythmia
NCT04276155· Phase 4· Centre Hospitalier de PAU· Source
Recruiting
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
NCT04951622· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up
NCT04290663· Phase 3· Centre Francois Baclesse· Source
Active, not recruiting
Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients
NCT03799835· Phase 3· UNICANCER· Source
Recruiting
Regenerative Stem Cell Therapy for Stroke in Europe 1-RESSTORE1
NCT03570450· Phase 1· University Hospital, Grenoble· Source
Completed
IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting
NCT02967289· Phase 3· UNICANCER· Source
Recruiting
Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
NCT02885753· Phase 3· Federation Francophone de Cancerologie Digestive· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A Phase 1b/2a first-in-human, multicentre, randomized, double-blind, placebo-controlled, multiple ascending dose followed by an open-label extension of S233107 in participants with spinocerebellar ataxia type 3
2025-525111-17-00· Phase 1/2· Institut De Recherches Internationales Servier IRIS· Source
Not yet recruiting
Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis
NCT05651880· Phase 3· University Hospital, Rouen· Source
Completed
Pilot study, open label, multicenter, evaluating dual antiretroviral therapy with long-acting cabotegravir/lenacapavir IMEA 069 - CALENDULA
2024-516028-33-01· Phase 3· Inst Medecine Epidemiologie Appliquee· Source
Completed
A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer
NCT06395753· Phase 2· Debiopharm International SA· Source
Completed
Impact of post-Acute respiratory distress syndrome COVID sedation on late neuroinflammation (PET-DEXDOCOVID)
NCT04352348· Phase 3· Assistance Publique Hopitaux De Paris· Source
Completed
Comparison of Corticosteroids vs Placebo on Duration of Ventilatory Support During Severe Acute Exacerbations of COPD Patients in the ICU
NCT04163536· Phase 3· Versailles Hospital· Source
Completed
An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)
2024-512717-41-00· Phase 2· Viracta Therapeutics Inc.· Source
Completed
OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC
NCT04713514· Phase 2· ARCAGY/ GINECO GROUP· Source
Completed
Prospective, randomised, placebo-controlled study of polyvalent
intravenous immunoglobulins for the treatment of primary Sjögren's
syndrome associated painful sensory neuropathies
NCT03700138· Phase 3· Les Hopitaux Universitaires De Strasbourg· Source
Report an error